Discover and read the best of Twitter Threads about #ASCO22VR
Most recents (2)
My thoughts on the DETERMINATION trial in myeloma presented in the Plenary session of #ASCO22 and published simultaneously in @NEJM #ASCO22VR
1) This is not a trial of transplant vs no transplant.
2) It's ~ the 5th RCT of early vs delayed transplant
1) This is not a trial of transplant vs no transplant.
2) It's ~ the 5th RCT of early vs delayed transplant
3) As with prior RCTs it shows prolonged PFS with early transplant but similar overall survival. That's because transplant works, but the timing doesn't matter as far as survival is concerned.
You do the same trial many times of course you are going to get the same results.
You do the same trial many times of course you are going to get the same results.
4) The timing is however affected by other factors besides survival.
Patient preference - some want to get it over with. Some want to love current life and do it later. We need to respect this.
Feasibility - some places cannot collect and store stem cells forever
Patient preference - some want to get it over with. Some want to love current life and do it later. We need to respect this.
Feasibility - some places cannot collect and store stem cells forever
Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
